ESMO GI 2022
Data Read-out



INVESTOR RELATIONS 2022

NEOIMMUNETECH

July 4, 2022

Disclaimer

This document has been prepared by NeoImmuneTech, Inc. (the "Company") solely for informational purpose as a presentation to investors and is strictly prohibited to be passed on, copied, or redistributed.

By participating in this presentation, the recipient of information hereby acknowledges and agrees to comply with the aforementioned restrictions, and such violations are subject to a violation of the Capital Market and Financial Investment Act. Projections contained in this document have not been subjected to individual verifiers. They are predictions of future, not past, events. This document explains the Company's anticipated business and financial performance, and includes expressions such as "anticipation", "forecast", "plan", "expectation", and "(E)".

The aforementioned "forecasted information" is influenced by future changes in the business environment and by definition contain uncertainties. Due to this inherent uncertainty, actual performance in the future may differ from what is stated or implied in the "forecasted information" presented in this document. Moreover, future forecasts in this presentation have been prepared given the current market situation and the Company's management direction and is subject to change depending on changes in either the market situation or strategy. The information presented or contained in these materials is subject to change without notice.

We are not responsible for any losses incurred in connection with the use of this material, including negligence or otherwise, by our employees. This document does not constitute solicitation for the recruitment, sale, or subscription of shares and no part of the document shall constitute an invitation to relevant contracts and arrangements or investment decisions.

NEOIMMUNETECH

Poster Presentation at

1. NIT-110 CPI-naïve R/R MSS-CRC (Ph.2a) Poster 152

2. NIT-110 CPI-naïve R/R PC (Ph.2a) Poster 139

NIT-110: Study protocol for MSS-CRC & PC

- CPI-naïve R/R solid tumors for two arms (MSS-CRC, PC)
- Pembrolizumab IV (Q3W; 200mg) + NT-I7 IM (Q6W; 1,200 μg/kg)





Primary Objectives

- ORR (Objective Response Rate)

MSS-CRC: Subject characteristics & safety

- As of April 29, 29 subjects enrolled, 27 were evaluable
- 79.3% of subjects with ≥ 1 liver metastasis

Characteristics	Categories	N = 29
Age in years, median (range)		56.0 (35, 81)
Gender, n (%)	Male Female	19 (65.5) 10 (34.5)
ECOG status, n (%)	0 1	8 (27.6) 21 (72.4)
Subjects with liver metastasis, n (%)		23 (79.3)

ECOG: Eastern Cooperative Oncology Group

- No Grade 4-5 AEs were observed

	Grade 1 n (%)	Grade 2 n (%)	Grade 3 n (%)	Grades 4-5 n (%)	All Grades n (%)
Number (%) of subjects with ≥1 TEAEs	8 (27.6)	9 (31.0)	6 (20.7)	0 (0.0)	23 (79.3)
Most frequently-reported TEAEs:					
Fatigue	4 (13.8)	4 (13.8)	1 (3.4)	0 (0.0)	9 (31.0)
Injection site reaction	5 (17.2)	2 (6.9)	0 (0.0)	0 (0.0)	7 (24.1)
Nausea	4 (13.8)	2 (6.9)	1 (3.4)	0 (0.0)	7 (24.1)
Fever	3 (10.3)	2 (6.9)	0 (0.0)	0 (0.0)	5 (17.2)
Rash maculo-papular	3 (10.3)	1 (3.4)	1 (3.4)	0 (0.0)	5 (17.2)
Vomiting	5 (17.2)	0 (0.0)	0 (0.0)	0 (0.0)	5 (17.2)
Flu-like symptoms	3 (10.3)	0 (0.0)	1 (3.4)	0 (0.0)	4 (13.8)

TEAE: Treatment-emergent adverse event

MSS-CRC: CD8-to-Treg ratio & TIL

- Observed favorable CD8-to-Treg ratio
- Subjects with PR showed the highest TIL infiltration

CD8-to-Treg ratio



** p<0.01, *** p<0.001, **** p<0.0001

Tumor Infiltrating Lymphocyte (TIL)



MSS-CRC: Efficacy (1)

- Efficacy was demonstrated in both groups ≤ 1 and ≥ 2 liver lesions, and iORR of 25% was observed in subjects with ≤ 1 liver lesions
- Median DoR was increased to 6.7 months compared to 4.6 months (ASCO data)

Efficacy summary, RECIST v1.1

	N = 27
Best overall response per RECIST v1.1, n (%):	
Complete response (CR)	0 (0.0)
Partial response (PR)	1 (3.7)
Stable disease (SD)	9 (33.3)
Progressive disease (PD)	17 (63.0)
ORR per RECIST v1.1, n (%)	1 (3.7)
DCR per RECIST v1.1, n (%)	10 (37.0)
DoR in months, median (min, max)	6.7 (6.7, 6.7)
ORR by number of prior therapies, n (%)	
≤2 (12)	1 (8.3)
≥3 (15)	0 (0.0)
ORR by number of liver lesions, n (%)	
≤1 (8)	1 (12.5)
≥2 (19)	0 (0.0)
ORR by sum of target lesion, n (%)	
≤100mm (16)	1 (6.3)
>100mm (11)	0 (0.0)

Efficacy summary, iRECIST

	N = 27
Best overall response per iRECIST, n (%):	
Immune complete response (iCR)	0 (0.0)
Immune partial response (iPR)	3 (11.1)
Immune stable disease (iSD)	8 (29.6)
Progressive disease immune unconfirmed (iUPD)	16 (59.3)
ORR per iRECIST, n (%)	3 (11.1)
DCR per iRECIST, n (%)	11 (40.7)
iDoR in months, median (min, max)	6.7 (4.2, 8.7)
iORR by number of prior therapies, n (%)	
≤2 (12)	2 (16.7)
≥3 (15)	1 (6.7)
iORR by number of liver lesions, n (%)	
≤1 (8)	2 (25.0)
≥2 (19)	1 (5.3)
iORR by sum of target lesion, n (%)	
≤100mm (16)	3 (18.8)
>100mm (11)	0 (0.0)

MSS-CRC: Efficacy (2)

- Median follow-up for MSS-CRC is 5.29 months
- The study medication showed durable anticancer activity and a manageable safety profile

Duration of treatment and response



NEOIMMUNETECH

Poster Presentation at

1. NIT-110 CPI-naïve R/R MSS-CRC (Ph.2a) Poster 152

2. **NIT-110 CPI-naïve R/R PC (Ph.2a) Poster 139**

PC: Subject characteristics & safety

- As of April 29, 32 subjects enrolled, 26 were evaluable
- 78.1% of subjects had liver metastasis

Characteristics	Categories	N = 32
Age in years, median (range)		66.0 (31, 81)
Gender, n (%)	Male Female	16 (50.0) 16 (50.0)
ECOG status, n (%)	0 1	10 (31.3) 22 (68.8)
Subjects with liver metastasis, n (%)		25 (78.1)

ECOG: Eastern Cooperative Oncology Group

- One AE in Grade 4 and no AE in Grade 5 were observed

	Grade 1 n (%)	Grade 2 n (%)	Grade 3 n (%)	Grade 4 n (%)	Grade 5 n (%)	All Grades n (%)
Number (%) of subjects with ≥1 TEAEs	10 (31.3)	9 (28.1)	4 (12.5)	1 (3.1)	0 (0.0)	24 (75.0)
Most frequently reported TEAEs:						
Fever	6 (18.8)	2 (6.3)	1 (3.1)	0 (0.0)	0 (0.0)	9 (28.1)
Injection site reaction	6 (18.8)	1 (3.1)	0 (0.0)	0 (0.0)	0 (0.0)	7 (21.9)
Fatigue	3 (9.4)	2 (6.3)	0 (0.0)	0 (0.0)	0 (0.0)	5 (15.6)
Rash	3 (9.4)	1 (3.1)	0 (0.0)	0 (0.0)	0 (0.0)	4 (12.5)
Chills	3 (9.4)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	3 (9.4)
Anorexia	1 (3.1)	1 (3.1)	0 (0.0)	0 (0.0)	0 (0.0)	2 (6.3)
Dry skin	2 (6.3)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	2 (6.3)

TEAE: Treatment-emergent adverse event

PC: CD8-to-Treg ratio & TIL

- Observed favorable CD8-to-Treg ratio
- TIL infiltration was highest in the subjects with PR and SD who showed a high T cell infiltration in a liver biopsy

CD8-to-Treg ratio



* p<0.05, ** p<0.01, *** p<0.001, **** p<0.0001

Tumor Infiltrating Lymphocyte (TIL)



- Partial Response (PR)
- Stable Disease (SD)
- Progressive Disease (PD)

ORR	Biopsy location	TIL score pre-Tx	TIL score post-Tx
PR	Lung	0	80
SD	Liver	1	80

PC: Efficacy

- Subjects with ≤1 liver lesion had significantly higher iDCR (63.6% vs 13.3%) and higher iORR (18.2% vs 0%), compared to subjects with ≥2 liver lesion
- Median DoR increased to 7.2 months from 6.1 months (ASCO data)

Efficacy summary, RECIST v1.1

	N = 26
Best overall response per RECIST 1.1, n (%):	
Complete response (CR)	0 (0.0)
Partial response (PR)	1 (3.8)
Stable disease (SD)	7 (26.9)
Progressive disease (PD)	18 (69.2)
ORR per RECIST 1.1, n (%)	1 (3.8)
DCR per RECIST 1.1, n (%)	8 (30.8)
DoR in months, median (min, max)	10.8 (10.8, 10.8
ORR by number of prior therapies, n (%)	
≤2 (18)	1 (5.6)
≥3 (8)	0 (0.0)
ORR by baseline sum of target lesion, n (%)	
≤100mm (20)	1 (5.0)
>100mm (6)	0 (0.0)
ORR by number of liver lesions, n (%)	
≤1 (11)	1 (9.1)
≥2 (15)	0 (0.0)
DCR by number of liver lesions, n (%)	
≤1 (11)	6 (54.5)
≥2 (15)	2 (13.3)

Efficacy summary, iRECIST

	N = 26
Best overall response per iRECIST, n (%):	
Immune complete response (iCR)	0 (0.0)
Immune partial response (iPR)	2 (7.7)
Immune stable disease (iSD)	7 (26.9)
Progressive disease immune unconfirmed (iUPD)	17 (65.4)
ORR per iRECIST, n (%)	2 (7.7)
DCR per iRECIST, n (%)	9 (34.6)
iDoR in months, median (min, max)	7.2 (3.5, 10.8)
iORR by number of prior therapies, n (%)	
≤2 (18)	2 (11.1)
≥3 (8)	0 (0.0)
iORR by baseline sum of target lesion, n (%)	
≤100mm (20)	2 (10.0)
>100mm (6)	0 (0.0)
iORR by number of liver lesions, n (%)	
≤1 (11)	2 (18.2)
≥2 (15)	0 (0.0)
iDCR by number of liver lesions, n (%)	
≤1 (11)	7 (63.6)
≥2 (15)	2 (13.3)

PC: mPFS by number of liver lesions

- Observed mPFS of 6 weeks in all subjects
- 18 weeks in subjects with ≤1 liver lesions, 6 weeks in subjects with ≥2 liver lesions



Number of subjects at risk:

<=1	11	11	5	4	2	2	2	1	1	1	1	1	0
>=2	15	13	1	1	0								

NT-I7 Development status

- After PoC is demonstrated from 1b/2a studies, a pivotal study design will be prepared



1. ALC: 2018 AACR, 2019 AACR, 2019 SITC, 2020 ASCO, 2020 SITC, 2021 ASCO, 2021 SNO, 2021 SITC, 2022 AACR, Clinical & Translational Immunology; e1168(2020), Clin Cancer Res. 2022 Mar 15;28(6):1229-1239
2. Tscm: 2021 SITC, 2022 ASCO
3. TIL: 2021 ASCO, 2021 SITC, 2022 ESMO GI, Clinical & Translational Immunology; e1168 (2020)
4. Tpex: 2022 AACR

Upcoming major events for 2H 2022

Estimated Data Read-Outs	**Conferences such as ESMO, SITC, ASH (TBD)** NIT-110: NSCLC, Pembrolizumab combo NIT-110: Selected cohorts, Pembrolizumab combo NIT-112: LBCL, CAR-T combo	Interim Analysis

* Data read-out plans are subject to change

THANK YOU !

NeoImmuneTech

[Korea Office] C-1003, Innovalley 253, Pangyo-ro, Bundang-gu,
Seongnam-si, Gyeonggi-do, Republic of Korea
ir@neoimmunetech.com

[Headquarters] 2400 Research Blvd., Suite 250, Rockville, MD 20850, USA
ir@neoimmunetech.com